Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the...
Main Authors: | Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, Justin DaSilva, Daniel Poston, Julio CC Lorenzi, Frauke Muecksch, Magdalena Rutkowska, Hans-Heinrich Hoffmann, Eleftherios Michailidis, Christian Gaebler, Marianna Agudelo, Alice Cho, Zijun Wang, Anna Gazumyan, Melissa Cipolla, Larry Luchsinger, Christopher D Hillyer, Marina Caskey, Davide F Robbiani, Charles M Rice, Michel C Nussenzweig, Theodora Hatziioannou, Paul D Bieniasz |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2020-10-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/61312 |
Similar Items
-
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
by: Emmie de Wit, et al.
Published: (2015-04-01) -
Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
by: Guodong Liu, et al.
Published: (2021-08-01) -
Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
by: Francesco Santoro, et al.
Published: (2021-01-01) -
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
by: Allison J. Greaney, et al.
Published: (2021-07-01) -
Titration methods for rVSV-based vaccine manufacturing
by: Jean-François Gélinas, et al.
Published: (2020-01-01)